- Home
- OFIX vs FDMT Comparison
OFIX vs FDMT Comparison
Compare OFIX & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OFIX | FDMT |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 515.6M |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OFIX | FDMT |
|---|---|---|
| Price | $12.80 | $9.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $17.25 | ★ $31.71 |
| AVG Volume (30 Days) | 228.9K | ★ 783.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $822,312,000.00 | $85,209,000.00 |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $6.24 | $70.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.85 | ★ 230194.60 |
| 52 Week Low | $10.25 | $2.89 |
| 52 Week High | $16.99 | $12.34 |
Technical Indicators
Market Signals| Indicator | OFIX | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 52.88 |
| Support Level | $12.33 | $8.41 |
| Resistance Level | $16.38 | $9.78 |
| Average True Range (ATR) | 0.41 | 0.65 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 88.71 | 51.85 |
Price Performance
Historical ComparisonAbout OFIX Orthofix Medical Inc. (DE)
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).